Bonfrer J M, Korse C M, Verstraeten R A, van Kamp G J, Hart G A, Kenemans P
Department of Clinical Chemistry, The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Amsterdam, The Netherlands.
Clin Chem. 1997 Mar;43(3):491-7.
The Byk LIA-mat CA125 II assay was compared with the Centocor IRMA CA125 II. Serum samples studied (n = 1012) were obtained from 652 apparently healthy females, 61 pregnant women, and 299 patients with benign and malignant gynecological tumors. The CA125 II assay value at the 95th percentile of the total healthy group was 29 kU/L for the LIA-mat and 32 kU/L for the Centocor assay. For the LIA-mat assay the 95th percentile was 31 kU/L (Centocor 36 kU/L) for the group < 45 years and 21 kU/L (Centocor 25 kU/L) for women > 55 years of age. By using ROC curves we found the optimal pretreatment Byk LIA-mat CA125 II value differentiating between benign and malignant ovarian tumors to be 95 kU/L. Pretreatment CA125 values > 1000 kU/L were detected in serum samples of patients with advanced epithelial ovarian cancer.
将拜耳LIA - mat CA125 II检测法与Centocor IRMA CA125 II检测法进行了比较。所研究的血清样本（n = 1012）取自652名表面健康的女性、61名孕妇以及299名患有良性和恶性妇科肿瘤的患者。对于整个健康组，LIA - mat检测法的CA125 II检测值在第95百分位数时为29 kU/L，Centocor检测法为32 kU/L。对于LIA - mat检测法，年龄<45岁组的第95百分位数为31 kU/L（Centocor为36 kU/L），年龄>55岁的女性为21 kU/L（Centocor为25 kU/L）。通过使用ROC曲线，我们发现区分良性和恶性卵巢肿瘤的最佳预处理拜耳LIA - mat CA125 II值为95 kU/L。在晚期上皮性卵巢癌患者的血清样本中检测到预处理CA125值>1000 kU/L。
